Prototyping of a biopreparation against caseous lymphadenitis

Caseous lymphadenitis (CLA), a chronic infectious illness that poses a serious threat to small ruminant productivity worldwide, is caused by Corynebacterium pseudotuberculosis. Infection rates can surpass 30 % in endemic areas like Brazil, Australia, and portions of Africa In the CIS countries, the issue is particularly relevant in regions of Central Asia and the Middle East. The article examines the development of new methods for controlling the disease, including the prototyping of biologics such as subunit vaccines, bacteriophages, probiotics, and biogenic nanomedicines, which offer promising prospects for effective treatment and prevention of caseous lymphadenitis. These innovative strategies are aimed at overcoming challenges associated with the chronic course of the disease and growing antibiotic resistance, making them an important direction in veterinary medicine. Among the strategies considered, the prototyping of a biologic based on Corynebacterium bacteriophages is noted as the most promising approach for veterinary medicine in the treatment and prevention of caseous lymphadenitis in small ruminants. The success of this strategy is based on the collection of Corynebacterium pseudotuberculosis phage isolates obtained by the authors, with established properties of production strains.